tetano
Editor, Senior Moderator
J Diabetes Investig
. 2022 Feb 26.
doi: 10.1111/jdi.13781. Online ahead of print.
Type 1 diabetes mellitus following COVID-19 RNA-based vaccine
Kanako Sakurai[SUP] 1 [/SUP], Daiki Narita[SUP] 1 [/SUP], Naomi Saito[SUP] 1 [/SUP], Takayuki Ueno[SUP] 1 [/SUP], Ryota Sato[SUP] 1 [/SUP], Satsuki Niitsuma[SUP] 1 [/SUP], Kazuhiro Takahashi[SUP] 2 [/SUP], Zenei Arihara[SUP] 1 [/SUP]
Affiliations
Abstract
The epidemic of coronavirus disease-2019 (COVID-19) is the major public health issue in the world. COVID-19 vaccines are one of the most effective strategies against COVID-19. Here we report a 36-year-old female patient who had thirst, polydipsia, polyuria, palpitations, loss of appetite, and fatigue 3 days after the first dose of COVID-19 RNA-based vaccines without a prior history of diabetes. Ten days after vaccination, she visited our hospital with diabetic ketoacidosis and was diagnosed with type 1 diabetes. Hyperglycemia (501 mg/dL), anion gap metabolic acidosis and ketonuria were observed. Glycated hemoglobin level was 7.0 %. Islet-related autoantibodies were all negative. The glucagon tolerance test revealed attenuated secretion of insulin. Human leukocyte antigen was haplotype DRB1*0405-DQB1*0401, which was associated with type 1 diabetes in Japan. The present case suggests that COVID-19 RNA-based vaccines might trigger the onset of type 1 diabetes, even in subjects without prior histories of diabetes.
Keywords: COVID-19 RNA-based vaccines; ketoacidosis; type 1 diabetes.
. 2022 Feb 26.
doi: 10.1111/jdi.13781. Online ahead of print.
Type 1 diabetes mellitus following COVID-19 RNA-based vaccine
Kanako Sakurai[SUP] 1 [/SUP], Daiki Narita[SUP] 1 [/SUP], Naomi Saito[SUP] 1 [/SUP], Takayuki Ueno[SUP] 1 [/SUP], Ryota Sato[SUP] 1 [/SUP], Satsuki Niitsuma[SUP] 1 [/SUP], Kazuhiro Takahashi[SUP] 2 [/SUP], Zenei Arihara[SUP] 1 [/SUP]
Affiliations
- PMID: 35220662
- DOI: 10.1111/jdi.13781
Abstract
The epidemic of coronavirus disease-2019 (COVID-19) is the major public health issue in the world. COVID-19 vaccines are one of the most effective strategies against COVID-19. Here we report a 36-year-old female patient who had thirst, polydipsia, polyuria, palpitations, loss of appetite, and fatigue 3 days after the first dose of COVID-19 RNA-based vaccines without a prior history of diabetes. Ten days after vaccination, she visited our hospital with diabetic ketoacidosis and was diagnosed with type 1 diabetes. Hyperglycemia (501 mg/dL), anion gap metabolic acidosis and ketonuria were observed. Glycated hemoglobin level was 7.0 %. Islet-related autoantibodies were all negative. The glucagon tolerance test revealed attenuated secretion of insulin. Human leukocyte antigen was haplotype DRB1*0405-DQB1*0401, which was associated with type 1 diabetes in Japan. The present case suggests that COVID-19 RNA-based vaccines might trigger the onset of type 1 diabetes, even in subjects without prior histories of diabetes.
Keywords: COVID-19 RNA-based vaccines; ketoacidosis; type 1 diabetes.
